BACKGROUND: Pediatric paired box 3:forkhead box protein O1 fusion-negative (PF-) rhabdomyosarcoma (RMS) represents a diverse spectrum of tumors with marked differences in histology, myogenic differentiation, and clinical behavior. METHODS: This study sought to evaluate the clinical and mutational spectrum of 24 pediatric PF-human RMS tumors with high levels of myogenic differentiation. Tumors were sequenced with OncoPanel v.2, a panel consisting of the coding regions of 504 genes previously linked to human cancer. RESULTS: Most of the tumors (19 of 24) arose at head/neck or genitourinary sites, and the overall survival rate was 100% with a median follow-up time of 4.6 years (range, 1.4-8.6 years). RAS pathway gene mutations were the most common mutations in PF-, highly differentiated RMS tumors. In addition, Hedgehog (Hh) and mechanistic target of rapamycin (mTOR) gene mutations with evidence for functional relevance (high-impact) were identified in subsets of tumors. The presence of Hh and mTOR pathway gene mutations was mutually exclusive and was associated with high-impact RAS pathway gene mutations in 3 of 4 Hh-mutated tumors and in 1 of 6 mTOR-mutated tumors. CONCLUSIONS: Interestingly, Hh and mTOR gene mutations were previously associated with rhabdomyomas, which are also known to preferentially arise at head/neck and genitourinary sites. Findings from this study further support the idea that PF-, highly differentiated RMS tumors and rhabdomyomas may represent a continuous spectrum of tumors.
INTRODUCTION
Rhabdomyosarcomas (RMSs) are cancers with skeletal muscle differentiation. Exclusive chromosomal translocations at t(2;13)(q35;q14) or t(1;13)(p36;q14) distinguish 2 disease categories.
1,2 Paired box 3:forkhead box protein O1 fusionpositive (PF1) tumors exhibit alveolar histology, aggressive clinical behavior, and unfavorable outcomes. In contrast, paired box 3:forkhead box protein O1 fusion-negative (PF-) RMS represents a diverse spectrum of tumors with marked differences in histology, myogenic differentiation, clinical behavior, and outcomes. 1, 2 The most common oncogenic mutations in human PF-RMS occur in RAS pathway genes. 3, 4 Genetically distinct mouse models of RMS reflect the clinicopathological heterogeneity of the human disease. [5] [6] [7] For example, mice that are haplo-insufficient for Patched 1 (Ptch1) 8 or express a constitutively hyperactive Smoothened (Smo) allele, 9, 10 which results in activated Hedgehog (Hh) signaling, develop highly differentiated tumors with muscle Interestingly, humans with nevoid basal cell carcinoma syndrome, which is associated with PTCH1 germline mutations, also are susceptible to developing highly differentiated RMS and FRM. 11 Finally, Hh pathway gene mutations have been detected in FRM tumors. 9 The association between Hh pathway gene mutations and highly differentiated myogenic tumors 9,11 led us to hypothesize that, similarly to human FRM, highly differentiated human RMS may carry Hh gene mutations and may be part of a continuous spectrum of highly differentiated myogenic tumors. 12 Several published studies have evaluated sequence variants in the human RMS genome. PTCH1 mutations were detected in a few nonalveolar RMS cases by fluorescence in situ hybridization 13, 14 ; however, the RMS sequencing cohorts published by Chen et al 3 and Shern et al 4 did not include any tumors with Hh pathway gene mutations (Supporting Table 1 ). In this study, we demonstrate that RAS pathway gene mutations are the most common mutations in PF-RMS tumors with high, rhabdomyoma-like levels of skeletal muscle differentiation. In addition, we identify Hh and mechanistic target of rapamycin (mTOR) gene mutations in subsets of tumors.
MATERIALS AND METHODS

Highly Differentiated RMS and Normal Human Muscle
Forty-one RMS cases labeled "highly differentiated" or "rhabdomyoma-like" were identified by L.A.T. during a central pathology review of tumors of children/adolescents enrolled in Children's Oncology Group (COG) RMS trials. Hematoxylin and eosin-stained sections were re-reviewed by L.A.T. to confirm the diagnosis of RMS as well as high levels of skeletal muscle differentiation (D3). In highly differentiated RMS tumors, myoblasts with ample eosinophilic, fibrillary cytoplasm were seen throughout tumor tissue, as previously described by Kodet et al. 15 Two cases were PF1. Ultimately, D3 histology was confirmed in 24 PF-cases (Fig. 1) . Corresponding normal tissue was not available. Data on the Intergroup Rhabdomyosarcoma Study stage and group, histology, primary tumor location, tumor size, age at diagnosis, sex, event-free survival (EFS), and overall survival (OS) were obtained from COG records (Table 1) . Figure 1 . Histology of paired box 3:forkhead box protein O1 fusion-negative rhabdomyosarcoma tumors with advanced muscle differentiation (D3). D3 histology is defined by a predominance of myoblasts, including elongated, multinucleated cells with abundant cytoplasm, throughout tumor tissue, as previously described by Kodet et al. 15 Representative images of tumor samples S12, S16, S2 and S3 are shown.
Discarded normal human skeletal muscle, obtained from 7 donors without a tumor history, served as control samples. Two PF-RMS tumors, which exhibited only occasional, scattered myoblasts throughout the tumor tissue and did not meet the criteria for highly differentiated RMS, were obtained from the National Development and Research Institutes, Inc. All studies involving human tissue samples were approved by the relevant institutional review boards (protocol 12-496, Dana-Farber Cancer Institute; CHS#06-42 and CHS#08-21, Joslin Diabetes Center; and EA1/056/14, Charit e). Informed consent was obtained from each participant or each participant's guardian.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were baked, deparaffinized, subjected to heat-induced antigen retrieval in a 10 mM sodium citrate buffer (pH 6), and stained against actin (1:200; Dako M0635), as previously described. 6, 9 Slides were lightly counterstained with hematoxylin.
DNA Isolation and Sequencing Analysis
Formalin-fixed, paraffin-embedded tumor tissue was scraped off 3 to 4 glass slides per tumor and skeletal muscle sample. All tissue samples were obtained before the initiation of chemotherapy and/or radiotherapy. DNA was isolated with the Covaris protocol, and the DNA concentration was determined with the PicoGreen doublestranded DNA reagent (Invitrogen). The DNA yield was adequate (>200 ng) for all skeletal muscle samples, 17 PF-tumor samples, and 2 PF1 tumor samples. Three PF-tumor samples were included in the sequencing run despite suboptimal DNA yields between 121.9 and 196.8 ng. Two tumors (tumor sample S25 and tumor sample S26) were excluded from sequencing analyses because of an insufficient DNA yield below 40 ng.
Sequencing Analysis
Sequencing was performed with OncoPanel v.2, an Agilent SureSelect custom-designed bait set consisting of the coding regions of 504 genes (Supporting Table 2 ) previously linked to human cancer. DNA from 22 PF-D3 RMS tumors and 8 normal human muscle samples was sequenced; 2 PF-D3 RMS tumors were excluded from the sequencing analysis because of insufficient DNA availability.
Samples were prepared for sequencing as previously described. 16 Briefly, before the library preparation, DNA was fragmented (Covaris sonication) to 250 bp and was further purified with Agencourt AMPure XP beads. Sizeselected DNA was ligated to specific adaptors during the library preparation (Illumina TruSeq). For all samples (including those with insufficient DNA yields), the size distribution was within the expected range after DNA fragmentation and library preparation. Each library was made with sample-specific barcodes and quantified with quantitative polymerase chain reaction (PCR). Libraries were pooled in an equal mass to a total of 500 ng for OncoPanel v.2 enrichment with the Agilent SureSelect hybrid capture kit. The captures were then sequenced on a total of 5 lanes of the HiSeq 2500 in the rapid run mode. Binary Alignment Map (BAM) files are available for download at the European Genome Archives (accession numbers EGAD00001003746 and EGAD00001003887).
Pooled sample reads were deconvoluted (demultiplexed) and sorted with the Picard tools. 17 Next, reads were aligned to the reference sequence b37 edition from the Human Genome Reference Consortium with bwa. 18 Duplicate reads were identified and removed with the Picard tools. 19 Alignments were further refined with the Genome Analysis Toolkit (GAT) for localized realignment around insertion and deletion (indel) sites. 20 For muscle samples, 94.1% to 98.1% of target bases were covered at > 303. We achieved >303 coverage in 89.2% to 99% of target bases in 14 PF-tumor samples, in 11.5% to 77.5% of target bases in 8 PF-samples, and in 95.1% to 97.8% of target bases in 2 PF1 tumors.
The mutation analysis for single-nucleotide variants (SNVs) was performed with MuTect v1.1.4 in the paired mode with the Centre d'Etude du Polymorphisme Humain (CEPH) lymphoblastoid cell line as the project normal. 21 Variants were annotated with Oncotator. We considered only SNVs that were nonsynonymous, were detected in a tumor fraction > 30%, were absent in normal skeletal muscle specimens, and were listed in the Exome Variant Server of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (Seattle, Washington; 6500-exome release) with a population frequency < 1% in either the African American or European American subset. Indels were called with Indelocator. 22 We considered only those indels found in an allele fraction > 25%. Finally, a copy number analysis was performed on all samples with Nexus 7.1 (BioDiscovery, Inc) after calculation of the sequencing coverage with Picard. All samples were compared with normal CEPH DNA and 1 of the skeletal muscle samples as a reference.
Alamut was used to perform an in silico pathogenicity analysis of RAS, Hh, mTOR, and NOTCH pathway gene mutations with 3 different algorithms (Sorting Intolerant From Tolerant, MutationTaster, and Polymorphism Phenotyping v2) and to evaluate the population frequency according to the Exome Aggregation Consortium browser. Sequence variations in Hh and mTOR pathway genes were verified by PCR. Mutations that were predicted to be damaging in silico were considered highimpact.
Statistical Analysis
EFS was defined as the time from study entry to the first occurrence of disease progression, disease relapse, or death. For those not experiencing one of these events, EFS was censored at last contact. Estimates of OS and EFS were calculated with the Kaplan-Meier method.
RESULTS
Terminal Muscle Differentiation in PF-D3 RMS
Our cohort included 24 PF-, highly differentiated human RMS tumors. These tumors contained many elongated, multinucleated myoblasts with abundant eosinophilic, fibrillary cytoplasm (Fig. 1 ), which were identified on hematoxylin and eosin-stained tissue sections and were consistent with highly differentiated D3 histology, as described by Kodet et al. 15 Marked cellular atypia, as evidenced by nuclear size/polymorphism and hyperchromasia, confirmed a diagnosis of RMS in all cases; Representative images of muscle samples M1 and M2, random rhabdomyosarcoma samples R1 and R2, paired box 3:forkhead box protein O1 fusion-negative, highly differentiated (D3) rhabdomyosarcoma samples S3, S12, S17, S19, S22 are shown. rhabdomyoma histology was excluded. All 24 tumors were initially classified and treated as embryonal RMS; 3 tumors were further described as spindle cell RMS (13%), 1 was described as botryoid RMS (4%), and 1 was described as RMS not otherwise specified (Table 1) .
To further explore the presence of terminal muscle differentiation features, actin expression was evaluated in 3 human skeletal muscle samples, 2 random PF-human RMS tumors obtained from the National Development and Research Institutes, Inc, and 5 PF-D3 human RMS tumors. As expected, there was strong cytoplasmatic actin staining in normal muscle fibers ( Fig. 2A) and minimal actin staining in the 2 random RMS specimens (Fig. 2B) . Consistent with their highly differentiated morphology, 4 of the 5 evaluated PF-D3 human RMS tumors (S3, S12, S17, and S22) exhibited strong actin staining (Fig. 2C) . Notably, the level of actin staining was not used to select PF-D3 RMS samples that were sequenced.
Clinical Characteristics of PF-D3 RMS
For the 24 PF-D3 RMS tumors included in this analysis, clinical and survival data were obtained from COG records. Eleven of these tumors (46%) originated in the genitourinary system, and 8 tumors (33%) arose at head and neck sites (Table 1) . Other primary sites were the retroperitoneum, mediastinum, chest well, pelvis, and paraspinal region (1 tumor each). The mean age at diagnosis was 8.1 6 6.3 years. Two cases (8%) were associated with distant metastases (stage IV). Twenty-two tumors (92%) were classified as stage I to III and as low/intermediate Intergroup Rhabdomyosarcoma Study (IRS) risk tumors (Table  1) . Two patients with stage III disease experienced relapse/ progression after 80 and 202 days, respectively. Another patient with stage I disease relapsed/progressed after 1.6 years. Notably, 1 of 3 recurrent cases was excluded from the sequencing analysis because of insufficient DNA availability. The OS rate was 100% with a median follow-up time of 4.6 years (range, 1.4-8.6 years; Fig. 3 ).
Frequent RAS Pathway Gene Mutations in PF-D3 RMS
The genetic underpinnings of 22 PF-D3 RMS tumors and 8 normal human muscle samples were examined with targeted Illumina sequencing (OncoPanel v. 2). We identified a total of 4 to 30 SNVs (nonsynonymous, not present in normal muscle samples, detected in a tumor fraction > 30%, and listed in the Exome Variant Server of the NHLBI Exome Sequencing Project with a population frequency < 1%) and indels (allele frequency > 25%; Fig. 4 and Supporting Tables 3 and 4 ) per tumor. Copy number variation analyses were performed for all tumors; however, the Nexus quality score was insufficient, and it was not possible to call any copy number variations except for high amplifications that were well above the noise level at the insulin-like growth factor 1 receptor locus in 2 samples (S1 and S19; data not shown). Supporting Figure 1 includes all mutated genes (n 5 16) detected in 4 or more PF-D3 RMS tumors. The most frequent aberrations in individual genes were detected in lysine (K)-specific methyltransferase 2C (MLL3; 18 tumors mutated), spectrin repeat containing nuclear envelope protein 1 (SYNE1; 6 tumors mutated), and LDL receptor-related protein 2 (LRP2; 7 tumors mutated).
We also detected aberrations in a number of genes that were previously found to be mutated in RMS, 3, 4 including NOTCH and RAS pathway genes (Fig. 4 and Supporting Table 1 ). Notably, the frequency of RAS gene mutations in PF-D3 tumors (45%) was comparable to that noted in previous sequencing cohorts of random PF-RMS tumors (29%-41%; Supporting Table 1) . 3, 4 The frequency of NOTCH gene mutations in PF-D3 RMS tumors (27%) was higher than that observed in previous cohorts of random PF-RMS tumors (0%-7%; Supporting Table 1) . 3, 4 Specifically, 10 NOTCH pathway gene mutations were detected in 6 tumors (Fig. 4) . Eight of these mutations (detected in 4 tumors) were predicted to be damaging in silico (Fig. 5A and Supporting Table 5 ); the NOTCH1 mutation in S11 and the mastermind-like transcriptional coactivator 2 (MAML2) mutation in S1 were predicted to be benign aberrations (Supporting Table 5 ).
Twelve RAS pathway gene mutations were detected in 10 of 22 PF-D3 RMS tumors sequenced (45%; Fig.  4) . Mutated RAS pathway genes in PF-D3 RMS included the following: neurofibromin 1 (NF1); HRas proto-oncogene, GTPase (HRAS); neuroblastoma RAS viral oncogene homolog (NRAS); mitogen-activated protein kinase kinase kinase 8 (MAP3K8); mitogen-activated protein kinase kinase kinase 1 (MAP3K1); and mitogenactivated protein kinase 3 (MAPK3). An in silico pathogenicity analysis predicted that 10 of 11 RAS pathway gene mutations were damaging according to at least 1 of 3 algorithms applied (Fig. 5A and Supporting Table 5 ). The NF1 mutation detected in tumor S3 was predicted to be a benign aberration (Supporting Table 5 ).
Hh and mTOR Pathway Gene Mutations in PF-D3 RMS
In addition to RAS and NOTCH, 2 other signaling pathways were highly represented among the genes mutated in PF-D3 RMS. Mutations in Hh and mTOR genes were not seen in previous sequencing cohorts of random PF-RMS tumors (Supporting Table 1) . 3, 4 First, 35 variants in Hh pathway genes were detected in 19 PF-D3 RMS tumors (Supporting Table 6 ). Four of these 35 variants were nonsynonymous, were not present in normal muscle samples, and were listed in the Exome Variant Server of the NHLBI Exome Sequencing Project with a population frequency < 1% (Fig. 4) . The SUFU negative regulator of Hedgehog signaling (SUFU) mutation and 2 of 3 PTCH1 mutations were subsequently confirmed by PCR (Supporting Table 5 ). PCR did not confirm the PTCH1 mutation (c.4048C>T) detected in S2 but identified an Figure 4 . Mutational spectrum of paired box 3:forkhead box protein O1 fusion-negative D3 rhabdomyosarcoma: mutations in RAS, NOTCH, Hh, and mTOR pathway genes and in genes previously found to be mutated in rhabdomyosarcoma. 3, 4 SNVs were considered if they were nonsynonymous, were detected in a tumor fraction > 30%, were not present in normal muscle samples, and were listed in the Exome Variant Server of the National Heart, Lung, and Blood Institute Exome Sequencing Project with a population frequency < 1%. Indels were considered if the allele frequency was >25%. The number of SNVs and indels refers to the total number of aberrations observed in the tumor. Notably, only 2 of the 3 recurrent cases were included in the sequencing analysis; 1 recurrent case was excluded because of insufficient DNA availability. E indicates event; GU, genitourinary; Hh, Hedgehog; HN, head and neck; indel, insertion and deletion; O, other; mTOR, mechanistic target of rapamycin; SNV, single-nucleotide variant.
alternative PTCH1 mutation (c.4225T>C) in the same tumor (Supporting Table 5 ). Also, all 4 Hh pathway gene mutations detected in PF-D3 RMS were predicted to be pathogenic by at least 1 algorithm in silico (Fig. 5A and Supporting Table 5 ). Second, 9 mTOR pathway gene mutations were identified in 8 PF-D3 RMS tumors (Fig.  4) . Mutated mTOR pathway genes included tuberous sclerosis 1 (TSC1), tuberous sclerosis 2 (TSC2), RPTOR independent companion of MTOR complex 2 (RIC-TOR), and MTOR. All 9 mTOR pathway gene mutations were confirmed by PCR except for the RICTOR mutations in S14 and S21 (insufficient amount of DNA available; Supporting Table 5 ). Six of these mutations (detected in 6 tumors) were predicted to be damaging in silico (Fig. 5A and Supporting Table 5 ); the TSC2 mutations in S16 and S18 and the TSC1 mutation in S17 were predicted to be benign aberrations (Supporting Table 5 ). It was not determined whether the observed Hh and mTOR pathway gene mutations activated or inactivated the function of the respective gene products.
In summary, we identified high-impact, likely damaging mutations with evidence for functional relevance in Hh genes in 4 tumors, in mTOR genes in 6 tumors, in NOTCH genes in 4 tumors, and in RAS genes in 10 tumors (Fig. 5A) . Interestingly, both Hh and mTOR gene mutations were previously associated with rhabdomyoma development. 9, 11, [23] [24] [25] All mTOR-and Hh-mutated PF-D3 RMS tumors arose at head/neck or GU sites and were diagnosed at stages I to III and in patients aged 1 to 10 years (Supporting Table 7 ). There were no tumors carrying concurrent mTOR and Hh pathway gene mutations (Fig. 5B) Previous studies established that RAS gene mutations are the most common mutations detected in all PF-RMS tumors. 3, 4 Hh gene aberrations in human RMS are rare, and mTOR pathway gene mutations have not been identified in human RMS thus far. 3, 4, 26, 27 On the other hand, RAS gene mutations were not found in a previously published cohort of FRMs, 9 and Hh and mTOR pathway gene mutations have been clearly associated with fetal and cardiac rhabdomyomas. 9, 11, [23] [24] [25] Highly differentiated RMS tumors and rhabdomyomas appear to share mutations in Hh and mTOR pathway genes. These are associated with frequent mutations in RAS pathway genes in highly differentiated RMS tumors but not rhabdomyomas.
Kodet et al 12 previously noted that highly differentiated RMSs and FRMs were difficult to distinguish histologically, and they suggested that fetal cellular rhabdomyomas and differentiated RMSs may be variant manifestations of the same disease. In our series described here, two-thirds of the PF-D3 RMS tumors arose at head/neck or genitourinary sites, and OS was substantially better than expected for children with RMS. 1 Interestingly, head/neck or genitourinary locations also are known to be common sites of origin of rhabdomyomas, which never metastasize and have excellent outcomes but exhibit locally aggressive growth and occasional multifocality. [28] [29] [30] As previously suggested by Kodet et al 12, 15 and ourselves, 9,11 highly differentiated RMS tumors and rhabdomyomas might form a continuous spectrum of tumors. This could have important implications for treatment. Similarly to the therapeutic requirements of rhabdomyomas, curing highly differentiated RMS tumors may depend on wide surgical resection rather than radiation and/or systemic chemotherapy.
Hh and mTOR signaling effects on skeletal muscle differentiation were previously evaluated. Activation of mTOR signaling stimulated muscle differentiation/regeneration. 31, 32 Similarly, activation of Hh signaling was shown to promote muscle differentiation, 33, 34 whereas Hh blockade impeded muscle regeneration after injury. 35 The differentiating effects of activated Hh and mTOR signaling in normal skeletal muscle could be consistent with a highly differentiated phenotype of Hh-and mTOR-mutated myogenic tumors. Also, Hh pathway activation in mice resulted in the formation of highly differentiated myogenic tumors, 8, 10 and PTCH1-inactivating mutations (resulting in Hh activation) were found in human FRMs. 9 Finally, in human PF-RMS, the expression of the Hh effectors GLI family zinc finger 1 (GLI1), GLI family zinc finger 3 (GLI3), and PTCH1 was previously correlated with low expression of the early myoblast marker Myod1 by Zibat et al. 36 Notably, this same study reported that Hh pathway activation in PF-RMS was associated with reduced survival, 36 whereas all 4 patients with Hh-mutated PF-D3 RMS tumors in the series first reported here survived. It is possible that the varied spectrum of PF-RMS comprises clinically distinct tumors with canonical Hh activation due to activating aberrations in Hh genes as well as tumors with noncanonical Hh activation due to aberrations in RMS-relevant upstream effectors.
PF-RMS represents a remarkably heterogeneous group of tumors. This series focuses specifically on those tumors that exhibit high, rhabdomyoma-like levels of differentiation. These tumors are rare. Although our study does not allow an estimate on what proportion of PF-RMS tumors are highly differentiated, Kodet et al previously reviewed the histology of 163 nonalveolar RMS tumors arising in the periorbital area. Fourteen of these 163 orbital tumors (9%) met D3 criteria for highly differentiated RMS. 15 Our study highlights the presence of frequent mutations in RAS pathway and rhabdomyomarelevant genes in these tumors. Data should be interpreted within the context of the study's limitations: 1) our sequencing cohort of 22 PF-D3 RMS cases is not necessarily representative but instead represents a convenience cohort, 2) our targeted sequencing approach included 504 cancer-relevant genes but not the entire genome, 3) a lack of paired germline samples prevented the distinction of germline and somatic mutations, and 4) it is possible that certain mutations were missed because of moderate target base coverage. Nevertheless, our findings further support the idea that highly differentiated RMS tumors and rhabdomyomas might form a continuous spectrum of tumors and share certain molecular and clinical characteristics. It will be important to further dissect the molecular and clinicopathological heterogeneity of PF-RMS in future studies evaluating larger representative cohorts of tumors.
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